GlassScriptPhysician profile
Adrian P Abreo
NPI 1023272895
$4,421.05
in general payments reported to CMS, 2019-2025
21 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $476 · 2021: $645 · 2022: $433 · 2023: $637 · 2024: $721 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,183.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $953.27 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $589.18 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $502.29 | 2020-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $390.74 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $373.16 | 2019-2024 | Injectafer |
| Travere Therapeutics, INC. | $324.22 | 2023-2025 | Filspari |
| Vifor Pharma, INC. | $215.58 | 2019-2024 | Veltassa |
| Glaxosmithkline, LLC. | $211.66 | 2021-2023 | Benlysta, Jesduvroq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $179.57 | 2023-2025 | |
| Amgen INC. | $134.43 | 2019-2021 | |
| Cook Medical LLC | $92.78 | 2019 | |
| Alexion Pharmaceuticals, INC. | $88.68 | 2024-2025 | Ultomiris |
| Fresenius USA Marketing, INC. | $75.55 | 2019-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $66.02 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $60.24 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.68 | 2024 | Jardiance |
| Nxstage Medical, INC. | $37.38 | 2021-2023 | Nxstage System One |
| Novartis Pharmaceuticals Corporation | $32.00 | 2025 | |
| Mallinckrodt Enterprises LLC | $21.07 | 2019 | |
| Terumo Medical Corporation | $17.02 | 2022 | |
| Genentech USA, INC. | $14.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Abreo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.